Protara Therapeutics Inc (TARA) - Total Liabilities
Based on the latest financial reports, Protara Therapeutics Inc (TARA) has total liabilities worth $13.06 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Protara Therapeutics Inc (TARA) cash flow conversion to assess how effectively this company generates cash.
Protara Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Protara Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Protara Therapeutics Inc (TARA) asset resilience to evaluate the company's liquid asset resilience ratio.
Protara Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Protara Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ring Energy Inc
NYSE MKT:REI
|
USA | $677.21 Million |
|
AVE Science & Technology Co Ltd
SHG:688067
|
China | CN¥93.09 Million |
|
Omega Flex Inc
NASDAQ:OFLX
|
USA | $19.74 Million |
|
West Wits Mining Ltd
AU:WWI
|
Australia | AU$22.12 Million |
|
I-Sheng Electric Wire & Cable Co Ltd
TW:6115
|
Taiwan | NT$3.07 Billion |
|
Cellectis
PA:ALCLS
|
France | €242.57 Million |
|
FVCBankcorp Inc
NASDAQ:FVCB
|
USA | $2.04 Billion |
|
Idun Industrier AB Series B
ST:IDUN-B
|
Sweden | Skr1.47 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Protara Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TARA market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protara Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protara Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Protara Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $13.06 Million | -8.83% |
| 2024-12-31 | $14.32 Million | +34.68% |
| 2023-12-31 | $10.63 Million | -5.12% |
| 2022-12-31 | $11.21 Million | +4.91% |
| 2021-12-31 | $10.68 Million | +172.92% |
| 2020-12-31 | $3.91 Million | +571.36% |
| 2019-12-31 | $583.00K | -81.06% |
| 2018-12-31 | $3.08 Million | -66.69% |
| 2017-12-31 | $9.24 Million | +81.93% |
| 2016-12-31 | $5.08 Million | +22.89% |
| 2015-12-31 | $4.13 Million | +76.78% |
| 2014-12-31 | $2.34 Million | -76.06% |
| 2013-12-31 | $9.77 Million | +135.26% |
| 2012-12-31 | $4.15 Million | -- |
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more